Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.

Abstract : PURPOSE OF REVIEW: Hepatitis C virus infection is the main cause of mixed cryoglobulinemia vasculitis. The disease expression of mixed cryoglobulinemia vasculitis is variable, ranging from mild clinical symptoms (purpura, arthralgia) to fulminant life-threatening complications (glomerulonephritis, widespread vasculitis). Treatment of hepatitis C virus-mixed cryoglobulinemia vasculitis may target either the viral trigger (hepatitis C virus) or the downstream B-cell arm of autoimmunity. This review focuses on recent advances in our understanding of the treatment of hepatitis C virus-mixed cryoglobulinemia vasculitis. RECENT FINDINGS: Aggressive antiviral therapy with Peg-IFNalpha and ribavirin should be considered as induction therapy for hepatitis C virus-mixed cryoglobulinemia vasculitis with mild to moderate disease severity and activity. In patients presenting with severe disease, an induction phase of immunosuppression is often necessary while awaiting the generally slow response to antiviral treatments. Combination therapy with rituximab and Peg-IFNalpha plus ribavirin appears logical as it may target both the viral trigger (hepatitis C virus) and cryoglobulin-producing B-cells. SUMMARY: Antiviral therapy and rituximab are the main therapeutic options in hepatitis C virus-mixed cryoglobulinemia vasculitis. Further studies are needed to better define the therapeutic strategy.
Type de document :
Article dans une revue
Current Opinion in Rheumatology, Lippincott, Williams & Wilkins, 2008, 20 (1), pp.23-8. 〈10.1097/BOR.0b013e3282f1330c〉
Liste complète des métadonnées

http://hal.univ-brest.fr/hal-00684157
Contributeur : Ghislaine Calvez <>
Soumis le : vendredi 30 mars 2012 - 16:43:03
Dernière modification le : mercredi 21 mars 2018 - 18:57:06

Identifiants

Collections

Citation

David Saadoun, Aurelien Delluc, Jean Charles Piette, Patrice Cacoub. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.. Current Opinion in Rheumatology, Lippincott, Williams & Wilkins, 2008, 20 (1), pp.23-8. 〈10.1097/BOR.0b013e3282f1330c〉. 〈hal-00684157〉

Partager

Métriques

Consultations de la notice

90